0810 GMT - Novo Nordisk's guidance cut is slightly greater than expected, with sales expectations lowered 3 percentage points and leaving consensus above the top end of the range, Jefferies analysts write. The EBIT target was also cut 3 percentage points. The lowered outlooks for sales and profit are likely 1-2 percentage points greater than expected, though potential consensus downgrades are likely greater due to currency. Sales of Wegovy missed by 7%, whilst Ozempic beat by 3%. Lower research and development and sales and distribution costs drove a 4% EBIT and 5% EPS beat. Focus now shifts to Wegovy trends and additional data readouts at the American Diabetes Association conference in June, Jefferies says. Shares rise 4.8%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
May 07, 2025 04:10 ET (08:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.